Nifoxipam

Source: Wikipedia, the free encyclopedia.
Nifoxipam
Legal status
Legal status
Identifiers
  • 5-(2-fluorophenyl)-3-hydroxy-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one
JSmol)
  • O=C1C(O)N=C(C2=CC=CC=C2F)C3=CC([N+]([O-])=O)=CC=C3N1
  • InChI=1S/C15H10FN3O4/c16-11-4-2-1-3-9(11)13-10-7-8(19(22)23)5-6-12(10)17-14(20)15(21)18-13/h1-7,15,21H,(H,17,20)
  • Key:UHFIFTRHLBAWGY-UHFFFAOYSA-N

Nifoxipam (3-hydroxydesmethylflunitrazepam, DP 370) is a benzodiazepine that is a minor metabolite of flunitrazepam and has been sold online as a designer drug.[1][2][3][4][5][6][7][8][9]

Nifoxipam produces strong tranquillising and sleep-prolonging effects and has much lower toxicity compared to lormetazepam and flunitrazepam in mice.[1]

See also

References

  1. ^ a b EP 0158267, Posselt K, Wagener HH, Gruber K,, "Pharmaceutical composition containing 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro- or 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one and process for their preparation", published 16 October 1985, assigned to Dolorgiet Beteiligungs-GmbH 
  2. ^ "Nifoxipam". New Synthetic Drugs Database. Archived from the original on 2016-11-01. Retrieved 2016-07-08.
  3. PMID 11259331
    .
  4. .
  5. ^ Kevin Flemen (August 2015). "Drug Facts - Newer Unregulated Drugs" (PDF). KFx. Retrieved 15 August 2015.
  6. ^ "Nifoxipam". WEDINOS.
  7. S2CID 25831532
    .
  8. .
  9. .